On September 17, 2019, inventor, Prof. Ricard L. Chang, successfully recruited Professor Harold H. Lee to PhorMed’s Scientific Advisory Board. Prof. Lee will advise on the company’s medical writing needs. He is credited for the publishing of 4 novels, 20 peer reviewed publications, and holds 4 patents, in the field of developmental biology. “Professor Lee has extensive knowledge in differentiation, the company’s primary mechanism of action and is a much welcomed addition to the company.” said Dr. Moretz, CEO.
PhorMed is pleased to add three members to its advisory board and is honored to announce Professor Xi Zheng, Professor Renping Zhou, and Sean O’Connell, Ph.D. These advisory board members have a combined 98 years of experience in oncology, neurology, and hematology, with 190 peer reviewed publications between them. “They are well received and are a great asset to the company. Their extensive knowledge of our technology and close workings with the inventor will help guide the technology to its end goals”, said Mr. Ben Chang, Chairman.
On August 1, 2019, PhorMed entered into multiple contracts to acquire five of Professor Ricard L. Chang’s patent inventions. These contracts cover patent assignments for the use of his compound, RP-323, in the treatment of Acute Myeloid Leukemia, Hodgkin’s Lymphoma, Parkinson’s disease, Stroke, and a new patent for treating platelets. The company’s goals for these technologies are to develop first line treatments and create a new class of drug for neurological diseases.